Improved Survival with HPV among African Americans with Oropharyngeal Cancer

Maria J. Worsham¹, Josena K. Stephen¹, Kang Mei Chen¹, Meredith Mahan², Vanessa Schweitzer¹, Shaleta Havard¹, and George Divine²

Abstract

Purpose: A major limitation of studies reporting a lower prevalence rate of human papilloma virus (HPV) in African American patients with oropharyngeal squamous cell cancer (OPSCC) than Caucasian Americans, with corresponding worse outcomes, was adequate representation of HPV-positive African American patients. This study examined survival outcomes in HPV-positive and HPV-negative African Americans with OPSCC.

Experimental Design: The study cohort of 121 patients with primary OPSCC had 42% African Americans. Variables of interest included age, race, gender, HPV status, stage, marital status, smoking, treatment, and date of diagnosis.

Results: Caucasian Americans are more likely to be HPV positive (OR = 3.28; P = 0.035), as are younger age (age < 50 OR = 7.14; P = 0.023 compared with age > 65) or being married (OR = 3.44; P = 0.016). HPV positivity and being unmarried were associated with being late stage (OR = 3.10; P = 0.047 and OR = 3.23; P = 0.038, respectively). HPV-negative patients had 2.7 times the risk of death as HPV-positive patients (P = 0.004). Overall, the HPV-race groups differed (log-rank P < 0.001), with significantly worse survival for HPV-negative African Americans versus (i) HPV-positive African Americans (HR = 3.44; P = 0.0012); (ii) HPV-positive Caucasian Americans (HR = 3.11; P < 0.049); and (iii) HPV-negative Caucasian Americans (HR = 2.21; P = 0.049).

Conclusions: HPV has a substantial impact on overall survival in African American patients with OPSCC. Among African American patients with OPSCC, HPV-positive patients had better survival than HPV-negative. HPV-negative African Americans also did worse than both HPV-positive Caucasian Americans and HPV-negative Caucasian Americans. This study adds to the mounting evidence of HPV as a racially linked sexual behavior life style risk factor impacting survival outcomes for both African American and Caucasian American patients with OPSCC. Clin Cancer Res; 19(9); 2486–92. ©2013 AACR.
Americans. For this study, we compared survival outcomes in HPV-positive African American patients. This study examined survival outcomes for HPV-positive and HPV-negative African Americans in a study cohort of 121 patients with primary OPSCC (42% African Americans), drawn from a large, clinically well-characterized multiethnic primary care patient population in the Detroit area.

A unique contribution of this study is the observation that among African American patients with OPSCC, HPV-positive patients had better survival than HPV negative. HPV-negative African Americans also did worse than both HPV-positive Caucasian Americans and HPV-negative Caucasian Americans. This study adds to the mounting evidence of HPV as a racially linked sexual behavior life style risk factor impacting survival outcomes for both African American and Caucasian American patients with OPSCC.

Translational Relevance
In African Americans with oropharyngeal squamous cell cancer (OPSCC), survival disparities are attributed to racial differences in the prevalence of human papilloma virus (HPV)–positive tumors. A major limitation of these studies is the lack of adequate representation of HPV-positive African American patients. This study examined survival outcomes for HPV-positive and HPV-negative African Americans in a study cohort of 121 patients with primary OPSCC (42% African Americans), drawn from a large, clinically well-characterized multiethnic primary care patient population in the Detroit area.

A unique contribution of this study is the observation that among African American patients with OPSCC, HPV-positive patients had better survival than HPV negative. HPV-negative African Americans also did worse than both HPV-positive Caucasian Americans and HPV-negative Caucasian Americans. This study adds to the mounting evidence of HPV as a racially linked sexual behavior life style risk factor impacting survival outcomes for both African American and Caucasian American patients with OPSCC.

Statistical analysis
All analyses were done using SAS 9.2. Categorical data are presented as count (percent) and continuous data as mean (SD). Univariate Wilcoxon rank sum, χ², and Fisher exact tests were used to examine individual associations with HPV status. Multivariable logistic regression was used to examine the effects of all other variables of interest on the outcomes of interest (HPV status and stage). Kaplan–Meier plots and log-rank tests were used to compare the survival times of HPV-positive and HPV-negative patients and of African Americans and Caucasians with HPV as compared with those without HPV. Cox regression was used to model the risk of death given age, race, gender, HPV status, stage, smoking status, marital status, treatment, and year of diagnosis. Adjustment for multiple comparisons was done using Hochberg’s method (14). Statistical significance was set at P < 0.05.

Results
Patient cohort characteristics
Of the 121 patients identified, 118 have HPV data, of which 67 are HPV negative and 51 HPV positive (43%). Patient characteristics (study variables) for the 118 OPSCC cohort are described in Table 1 and included 68 Caucasian Americans, 49 African Americans, and 1 unknown race. The median length of follow-up was 46.8 months (range 0.1 to 194 months).

HPV prevalence and associated outcomes
In univariate tests (Table 1), being HPV positive was associated with Caucasian race (P = 0.024), not smoking (P = 0.059), and being married (P = 0.004). In multiple logistic regression modeling of 88 OPSCC with complete data (Table 2), Caucasian Americans are more likely to be HPV positive (OR = 3.28; P = 0.035), as are younger age (age < 50 OR = 7.14; P = 0.023 compared with age > 65) or being married (OR = 3.44; P = 0.016). In a model using stage (early or late) as the outcome (Supplementary Table S1) and controlling for age, race, gender, smoking status, and year of diagnosis, late stage (stage III & IV) was associated with HPV–positive status [OR = 3.10; 95% confidence interval (CI) 1.01–9.45; P = 0.047] and as was being unmarried (OR = 3.23, 95% CI 1.06–9.78; P = 0.038).

HPV status and survival outcomes
Of the 121 patients with survival data available, 56 lived and 65 died. Patients who are HPV positive have significantly higher survival probability than patients who are HPV negative (univariate log-rank P = 0.003, Fig. 1). The median survival time for HPV-negative patients was 2.2 years (95% CI 1.3–5.2), but for HPV-positive patients median survival was over 13 years.

Cox regression given age, race, gender, HPV status, stage, treatment, smoking status, marital status, and year of diagnosis indicated that HPV-negative patients had 2.7 times the risk of death compared with HPV-positive patients (95% CI 1.37–5.31; P = 0.004; Table 3), late-stage patients had worse survival than early-stage patients (OR = 2.44; 95% CI 1.15–5.16; P = 0.020), and current smokers had 3.4 times the risk of death versus...
never-smokers (95% CI 1.13–10.38; \( P = 0.030 \)). Race as African American was not independently associated with worse outcome in the entire cohort in multivariate analysis. No interactions were significant.

Survival of the HPV and race groups (combined to form 4 groups), differed significantly overall (log-rank \( P < 0.001 \), Fig. 2, Table 4). HPV-negative African Americans had worse overall survival than HPV-positive African Americans (HR = 3.44, raw \( P = < 0.001 \), Hochberg adjusted \( P = 0.0012 \)), worse survival than HPV-positive Caucasian Americans (HR = 3.11; raw \( P = 0.012 \); adjusted \( P = 0.0496 \)), and worse survival than HPV-negative Caucasian Americans (HR = 2.21; raw \( P = 0.02 \); adjusted \( P = 0.0496 \)). HPV-positive African American patients had no differences in survival from that of HPV-positive and HPV-negative Caucasian Americans (\( P = 0.84 \) and \( P = 0.66 \), respectively).

Also, HPV-positive Caucasian Americans and HPV-negative Caucasian Americans with OPSCC showed no differences in survival outcomes (\( P = 0.84 \)).

### Discussion

HPV is now regarded, in addition to tobacco and alcohol (15), as a causative agent for OPSCC (16) and an independent risk factor for OPSCC (17, 18). The association between HPV and HNSCC (for both incidence and prognosis) is strongest for OPSCC. HPV-positive OPSCC has been noted as a distinct variant of HNSCC characterized by

### Table 1. All patient characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>Response</th>
<th>All patients</th>
<th>HPV negative ( (N = 67) )</th>
<th>HPV positive ( (N = 51) )</th>
<th>( P ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery</td>
<td>No</td>
<td>67 (56.8%)</td>
<td>41 (61%)</td>
<td>26 (51%)</td>
<td>0.267</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>51 (43.2%)</td>
<td>26 (39%)</td>
<td>25 (49%)</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>( \leq 50 )</td>
<td>17 (14.4%)</td>
<td>6 (9%)</td>
<td>11 (22%)</td>
<td>0.149</td>
</tr>
<tr>
<td></td>
<td>51–65</td>
<td>60 (50.9%)</td>
<td>37 (55%)</td>
<td>23 (45%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;65</td>
<td>41 (34.8%)</td>
<td>24 (36%)</td>
<td>17 (33%)</td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td>White</td>
<td>68 (57.6%)</td>
<td>32 (48%)</td>
<td>36 (71%)</td>
<td>0.024</td>
</tr>
<tr>
<td></td>
<td>Black</td>
<td>49 (41.5%)</td>
<td>34 (51%)</td>
<td>15 (29%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Unknown</td>
<td>1 (0.9%)</td>
<td>1 (1%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td>Male</td>
<td>92 (78.0%)</td>
<td>49 (73%)</td>
<td>43 (84%)</td>
<td>0.181</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>26 (22.0%)</td>
<td>18 (27%)</td>
<td>8 (16%)</td>
<td></td>
</tr>
<tr>
<td>Stage</td>
<td>Early</td>
<td>25 (21.2%)</td>
<td>18 (27%)</td>
<td>7 (14%)</td>
<td>0.206</td>
</tr>
<tr>
<td></td>
<td>Late</td>
<td>90 (76.3%)</td>
<td>47 (70%)</td>
<td>43 (84%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other/missing</td>
<td>3 (2.5%)</td>
<td>2 (3%)</td>
<td>1 (2%)</td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td>Current</td>
<td>63 (53.4%)</td>
<td>42 (63%)</td>
<td>21 (41%)</td>
<td>0.059</td>
</tr>
<tr>
<td></td>
<td>Past</td>
<td>40 (33.9%)</td>
<td>19 (28%)</td>
<td>21 (41%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Never</td>
<td>15 (12.7%)</td>
<td>6 (9%)</td>
<td>9 (18%)</td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td>Surgery alone</td>
<td>15 (12.7%)</td>
<td>12 (18%)</td>
<td>3 (6%)</td>
<td>0.031</td>
</tr>
<tr>
<td></td>
<td>Surgery + radiation</td>
<td>18 (15.3%)</td>
<td>8 (12%)</td>
<td>10 (20%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Surgery + radiation + chemo</td>
<td>18 (15.3%)</td>
<td>6 (9%)</td>
<td>12 (24%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Radiation alone (no surgery)</td>
<td>36 (30.5%)</td>
<td>20 (30%)</td>
<td>16 (31%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Radiation + chemo (no surgery)</td>
<td>22 (18.6%)</td>
<td>13 (19%)</td>
<td>9 (18%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>No treatment</td>
<td>9 (7.6%)</td>
<td>8 (12%)</td>
<td>1 (2%)</td>
<td></td>
</tr>
<tr>
<td>Married</td>
<td>Not married</td>
<td>49 (43.4%)</td>
<td>35 (56%)</td>
<td>14 (28%)</td>
<td>0.004</td>
</tr>
<tr>
<td></td>
<td>Married</td>
<td>64 (56.6%)</td>
<td>28 (44%)</td>
<td>36 (72%)</td>
<td></td>
</tr>
<tr>
<td>Status</td>
<td>Alive</td>
<td>54 (45.8%)</td>
<td>23 (34%)</td>
<td>31 (61%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dead</td>
<td>64 (54.2%)</td>
<td>44 (66%)</td>
<td>20 (39%)</td>
<td></td>
</tr>
<tr>
<td>Year of diagnosis</td>
<td>1998.2 ± 3.8</td>
<td>1996.3 ± 4.0</td>
<td>1997.7 ± 3.9</td>
<td>0.090</td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Bold, \( P < 0.05 \).

### Table 2: Multivariable associations with positive HPV status \( (N = 88; \) positive = 43, negative = 45)

<table>
<thead>
<tr>
<th>Variable</th>
<th>ORs (95% CI)</th>
<th>( P ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ( (51–65 \text{ vs. } &gt;65) )</td>
<td>1.25 (0.41–3.80)</td>
<td>0.690</td>
</tr>
<tr>
<td>Age ( \leq 50 \text{ vs. } &gt;65 )</td>
<td>7.14 (1.31–39.00)</td>
<td>0.023</td>
</tr>
<tr>
<td>Race (White vs. Black)</td>
<td>3.28 (1.09–9.87)</td>
<td>0.035</td>
</tr>
<tr>
<td>Gender (Male vs. Female)</td>
<td>1.63 (0.42–6.32)</td>
<td>0.476</td>
</tr>
<tr>
<td>Stage (Early vs. Late)</td>
<td>1.74 (0.12–24.29)</td>
<td>0.681</td>
</tr>
<tr>
<td>Smoke (Never vs. Current)</td>
<td>1.03 (0.22–4.83)</td>
<td>0.970</td>
</tr>
<tr>
<td>Smoke (Past vs. Current)</td>
<td>1.48 (0.48–4.57)</td>
<td>0.501</td>
</tr>
<tr>
<td>Married (Yes vs. No)</td>
<td>3.44 (1.26–9.33)</td>
<td>0.016</td>
</tr>
<tr>
<td>Year of diagnosis</td>
<td>1.10 (0.96–1.26)</td>
<td>0.189</td>
</tr>
</tbody>
</table>

**NOTE:** Bold, \( P < 0.05 \).
high prevalence of HPV infection, better patient outcome, nonkeratinizing histology, and overexpression of p16 (19), with worse outcomes in OPSCC for African Americans compared with Caucasian Americans partially explained by less HPV-positive cases in African Americans (9, 10).

Overall HPV prevalence in this cohort was 43%, with diagnosis years ranging from 1990 through 2004 and younger patients <50 years of age were significantly more likely to be HPV positive. Chaturvedi and colleagues (18) reported a higher HPV prevalence in OPSCC of approximately 70% during 2000 to 2004. They found that HPV-positive patients diagnosed from 1984 to 2004 were significantly younger and more likely to be white. The study attributed increases in the population-level incidence and survival of OPSCC in the United States since 1984 to HPV infection, with an estimation that, by 2020, HPV will cause more oropharyngeal cancers than cervical cancers in the United States (18).

In this study, with 42% African Americans, prevalence of HPV was lower in African American than Caucasian American patients with OPSCC. Caucasian Americans patients were significantly more likely to be HPV positive than African American patients supporting HPV tumor status as a disparate determinant in African American patients with OPSCC (9, 10, 20, 21). There is conclusive evidence that HPV has a strong association between sexual behavior and OPSCC, which has been linked to an increase in the number of oral sex partners (22–25). Studies of racial differences in sexual behaviors (26, 27) suggest that a higher proportion of whites engage in oral sex. These sexual behavior differences are thought to be one piece of the puzzle (28) for the reported racial disparity of HPV prevalence in OPSCC and might explain the higher rate of HPV-positive oropharyngeal cancers in whites (vs. blacks; refs. 9, 10, 20, 21).

In this study, married patients were more likely to be HPV positive than unmarried OPSCC. The latter is the opposite of what was found in a report that never-married status may be a surrogate for sexual practices associated with HPV transmission based on the dramatically elevated and reciprocal risk of second primary anogenital and oral cavity/pharyngeal cancers risk among never-married men compared with ever-married men (29). Significant changes in marriages and living together dynamics have occurred over the years, resulting in changes in sexual behavior and cohabitation choices emphasizing the need for larger studies that address sexual practices to further define the intervention between marital status and HPV infection in OPSCC.

Our study supports improved survival for HPV positive as compared with HPV-negative OPSCC. Tumor HPV status has been shown to be the single strongest predictor, followed by measures of tobacco exposure and tumor stage (30). Overall, in multivariate associations, HPV16-negative patients had a significantly poorer survival probability than HPV positive, a finding that concurs with several reported studies (HR = 2.9; P = 0.003). Also, late-stage patients had better survival than early-stage OPSCC (OR = 2.21; P = 0.034) and support studies of late stage as an important predictor of poor survival with patients dying of uncontrollable loco-regional disease (31).

Current smokers were nearly 4 times more likely to die than never smokers (OR = 3.8; P = 0.019); no difference in survival for past smokers was noted. Tobacco exposure has been associated with clinical trial outcome (32) and nicotine has been reported to reduce the cytotoxic effects of cisplatin and radiation of HNSCC cell lines (33). A recent finding of an increase of risk of OPSCC progression and death as a direct function of tobacco exposure at diagnosis and during therapy, independent of tumor p16 status and treatment (34) concurs with tumor HPV status as a strong independent prognostic factor for survival in OPSCC. (17). Thus, the most important risk factors for development of head and neck cancer, HPV and smoking, have utility as predictors of response to therapy and patient survival and likely determine the molecular profile of this disease.

Late-stage OPSCC were more likely to be HPV-positive status (OR = 3.10; P = 0.47) and unmarried (OR = 3.23; P = 0.038) as compared with early-stage patients. HPV-positive HNSCC are more likely to be detected as late-stage cancers.

Table 3. Multivariate associations with death (N = 108, death = 59, censored = 49)

<table>
<thead>
<tr>
<th>HR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (&gt;65)</td>
<td>2.67 (1.43–4.99)</td>
</tr>
<tr>
<td>Age (≤ 50)</td>
<td>1.49 (0.63–3.54)</td>
</tr>
<tr>
<td>Race (black)</td>
<td>1.15 (0.64–2.07)</td>
</tr>
<tr>
<td>Gender (male)</td>
<td>2.12 (1.02–4.42)</td>
</tr>
<tr>
<td>HPV (negative)</td>
<td>2.69 (1.37–5.31)</td>
</tr>
<tr>
<td>Stage (late)</td>
<td>2.44 (1.15–5.16)</td>
</tr>
<tr>
<td>Both radiation &amp; chemo</td>
<td>2.89 (1.47–5.72)</td>
</tr>
<tr>
<td>Neither radiation &amp; chemo</td>
<td>2.53 (1.18–5.43)</td>
</tr>
<tr>
<td>Smoking (current)</td>
<td>3.42 (1.13–10.38)</td>
</tr>
<tr>
<td>Smoking (past)</td>
<td>1.51 (0.49–4.70)</td>
</tr>
<tr>
<td>Married (yes)</td>
<td>1.18 (0.64–2.18)</td>
</tr>
<tr>
<td>Year of diagnosis</td>
<td>0.95 (0.87–1.02)</td>
</tr>
</tbody>
</table>

NOTE: Bold, P < 0.05.
Worsham et al.

among African Americans, those that were HPV positive did

also risk stratify patients and help direct treatment plans

which traditionally indicate poor prognosis (24, 35, 36).

Despite this, survival has been shown to be better for patients

A unique contribution of this study is the observation that

which were HPV positive did better than those that were HPV negative (HR = 3.44; raw

P = 0.0001; Hochberg adjusted P = 0.0012), a finding not

previously reported presumably due to a paucity of multi-

ethnic cohorts and limited number of African American

patients with OPSCC. This is illustrated in the frequency

distribution of HPV by race in TAX 324 by Settle and

colleagues (9), which had only 1 African American

HPV-positive OPSCC (of 28 African Americans). Chernock

and colleagues (10) had 3 HPV-positive cases (of 26 African

Americans), and Weinberger and colleagues (21) had zero

HPV-positive African American with OPSCC (of 16 African

Americans with HPV data). For HPV and race groups, HPV-

negative African Americans had worse overall survival than

both HPV-positive and HPV-negative Caucasian Americans

(P = 0.0005 adjusted and P = 0.01 raw; P = 0.05 adjusted, respectively). HPV-negative African

American patients were more likely to be current smokers

(79%) than HPV-positive African Americans (31%), HPV-

negative Caucasian Americans (43%), or HPV-positive Cau-

sian Americans (34%; P = 0.005). However, even if the

comparisons among the 4 race/HPV groups are made in a

multivariable model adjusted for smoking and other factors,

the HPV-negative African American patients still do worse

than the other groups. A larger sample size and assessment

of genetic heterogeneity using ancestry informative marker

analysis may be needed to further explain this.

The primary health care environment of the Henry Ford

Health System, which has a high proportions of insured

patients (39), may partially explain the lack of survival

differences between African Americans and Caucasian

Americans in this OPSCC cohort. Our study, highlighting

survival differences based only on HPV-race groups, indi-

cates that HPV has a substantial impact on overall survival

in African Americans with OPSCC. HPV-negative African

Americans not only had worse survival than HPV-positive

African Americans, but also did worse than both, HPV-

positive Caucasian Americans and HPV-negative Caucasian

Americans. Whether these findings reflect cultural differ-

ences in sexual lifestyle preferences evident from a signifi-

cantly lower prevalence for HPV in the African American

OPSCC group is not estimable from this study. Drawn from

a multiethnic access to care population, this study adds to

the mounting evidence of HPV as a likely racially linked

sexual behavior life style risk factor impacting survival

outcomes for both African American and Caucasian Amer-

ican patients with OPSCC.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors’ Contributions

Conception and design: M.J. Worsham

Development of methodology: M.J. Worsham, J.K. Stephen, K.M. Chen

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M.J. Worsham, J.K. Stephen, K.M. Chen, V. Schweitzer

Analysis and interpretation of data (e.g., statistical analysis, biosta-


Writing, review, and/or revision of the manuscript: M.J. Worsham, J.K. Stephen, K.M. Chen, M. Mahan, V. Schweitzer, G. Divine

Table 4. Cox proportional survival hazard model for race and HPV with contrasts (N = 116)

<table>
<thead>
<tr>
<th></th>
<th>HR (95% CI)</th>
<th>Raw P value</th>
<th>Adjusted P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV- CA (Ref)</td>
<td>1.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV- AA vs. HPV- CA</td>
<td>2.21 (1.19–4.08)</td>
<td>0.012</td>
<td>0.0496</td>
</tr>
<tr>
<td>HPV- C vs. HPV- CA</td>
<td>0.71 (0.28–1.80)</td>
<td>0.469</td>
<td>0.8403</td>
</tr>
<tr>
<td>HPV- AA vs. HPV- CA</td>
<td>0.64 (0.32–1.30)</td>
<td>0.220</td>
<td>0.6600</td>
</tr>
<tr>
<td>Contrasts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV- AA vs. HPV- CA</td>
<td>3.11 (1.28–7.58)</td>
<td>0.012</td>
<td>0.0496</td>
</tr>
<tr>
<td>HPV- AA vs. HPV- AA</td>
<td>3.44 (1.79–6.60)</td>
<td>&lt;0.001</td>
<td>0.0012</td>
</tr>
<tr>
<td>HPV- CA vs. HPV- AA</td>
<td>1.10 (0.42–2.88)</td>
<td>0.840</td>
<td>0.8403</td>
</tr>
</tbody>
</table>

Abbreviations: AA, African American; CA, Caucasian Americans
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 19, 2012; revised February 14, 2013; accepted March 11, 2013; published OnlineFirst March 26, 2013.

References

Improved Survival with HPV among African Americans with Oropharyngeal Cancer


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-12-3003

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2013/03/26/1078-0432.CCR-12-3003.DC1

Cited articles
This article cites 35 articles, 10 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/19/9/2486.full#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/19/9/2486.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.